1. Home
  2. Live Updates
  3. Urologic oncology program

Live Breaking News & Updates on Urologic oncology program

Stay informed with the latest breaking news from Urologic oncology program on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Urologic oncology program and stay connected to the pulse of your community

Testicular Cancer: Expert Advice for Early Detection

Vignesh T. Packiam, MD, director of Clinical and Translational Research in Urologic Oncology and a urologic oncologist in the Urologic Oncology Program at Rutge

United-states , American , Vignesht-packiam , Translational-research-in-urologic-oncology , Rutgers-cancer-institute-of-new-jersey , American-cancer-society , Cancer-center , Rwjbarnabas-health , New-brunswick , American-cancer , Translational-research

Dr Gong on the EMBARK Trial Investigating Enzalutamide in nmCSPC

Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Jun-gong , Urologic-oncology-program , Samuel-oschin-comprehensive-cancer-institute , Pancreatic-cancer-research-group , Gastrointestinal-disease-research-group , Colorectal-cancer , Cedars-sinai-cancer , Edars-sinai-cancer , Prostate-cancer , Onclive-tv , Embark , Enzalutamide

Dr Gong on the Current Treatment Armamentarium in mHSPC

Jun Gong, MD, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Jun-gong , Gastrointestinal-disease-research-group , Samuel-oschin-comprehensive-cancer-institute , Pancreatic-cancer-research-group , Urologic-oncology-program , Colorectal-cancer , Cedars-sinai-cancer , Edars-sinai-cancer , Prostate-cancer , Onclive-tv ,

Cedars-Sinai Cancer 2023 Research and Program Highlights

A roundup of 2023 medical discoveries and innovations at Cedars-Sinai Cancer.

Netherlands , United-states , Colorado , Beverly-hills , American , Ekihiro-seki , Lali-medina-kauwe , Simon-knott , Srinivas-gaddam , Kevin-scher , Shelly-lu , Kristin-taylor

Cedars-Sinai Cancer 2023 Research and Program Highlights

A roundup of 2023 medical discoveries and innovations at Cedars-Sinai Cancer.

Netherlands , United-states , Colorado , Beverly-hills , American , Shelly-lu , Kristin-taylor , Arun-sharma , Sara-ghandehari , Omid-hamid , Alexandra-gangi , Arash-asher

Long-Term OS Data Confirm Pembrolizumab/Lenvatinib as a Primary Frontline Option in Advanced RCC

Thomas Hutson, DO, PharmD, expands on previously reported findings from the CLEAR study, detailed updated data from the final OS analysis, and emphasized how these results support the use of this regimen as a mainstay treatment option in the frontline setting for patients with advanced RCC.

Texas , United-states , Baylor-university , Dallas , Texas-college , Thomas-hutson , Astellas-pharma , Bristol-myers-squibb , Urologic-cancer-research , Texasam-college-of-medicine , Treatment-center-at-baylor-university-medical , Johnson

Dr Hutson on the Final OS Analysis of the CLEAR Study in Advanced RCC

Thomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.


Baylor-university , Texas , United-states , Texas-college , Thomas-hutson , Baylor-university-medical-center , Treatment-center , Texasam-college-of-medicine , Urologic-cancer-research , Urologic-oncology-program , Texas-oncology , New-england-journal

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Canada , Japan , United-states , Tokyo , American , John-infanti , Thomas-hutson , Damini-chokshi , Julie-cunningham , Peter-dannenbaum , Gregory-lubiniecki , Corina-dutcus


acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

United-states , Canada , Tokyo , Japan , American , Corina-dutcus , Thomas-hutson , Peter-dannenbaum , John-infanti , Gregory-lubiniecki , Julie-cunningham , Damini-chokshi

LENVIMA Plus KEYTRUDA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib

As First-Line Treatment For Patients With Advanced Renal Cell Carcinoma After four years of follow-up, LENVIMA plus KEYTRUDA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial Final results ...

Canada , Tokyo , Japan , United-states , American , Corina-dutcus , Thomas-hutson , Gregory-lubiniecki , Texas-oncology-at-baylor-sammons-cancer-center , Urologic-oncology-program , American-society-of-clinical-oncology , Urologic-cancer-research